References
- Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–399. https://doi.org/10.1001/archsurg.1992.01420040034005. PMID:1558490
- Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609. https://doi.org/10.1056/NEJMoa1310460. PMID:24521106
- Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206. https://doi.org/10.1200/JCO.2009.23.4799. PMID:19917835
- Amin MB, Edge S, Greene F. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2017:p. 563–583.
- Thompson JF, Shaw HM. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome? Ann Surg Incol. 2002;9(8):719–722. https://doi.org/10.1007/BF02574492.
- Essner R, Chung MH, Bleicher R, Hsueh E, Wanek L, Morton DL. Prognostic implictions of thick (≥ 4 mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol. 2002;9(8):754–761. https://doi.org/10.1245/ASO.2001.06.024%2010.1007/BF02574497. PMID:12374658
- Fairbairn NG, Orfaniotis G, Butterworth M. Sentinel lymph node biopsy in thick malignant melanoma: A 10-year single unit experience. JPRAS. 2012;65(10):1396–1402. PMID:22552263
- Gajdos C, Griffith KA, Wong SL, et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer. 2009;115(24):5752–5760. https://doi.org/10.1002/cncr.24660. PMID:19827151
- Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C. Sentinel lymph node mapping for thick (≥ 4 mm) melanoma: should we be doing it? Ann Surg Oncol. 2003;10(4):408–415. https://doi.org/10.1245/ASO.2003.03.055. PMID:12734090
- Caracò C, Celentano E, Lastoria S, Botti G, Ascierto PA, Mozzillo N. (2004) Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters. Ann Surg Oncol. 2004;11(3 Suppl):198S–202S. https://doi.org/10.1245/ASO.2004.12.921%2010.1007/BF02523628. PMID:15023751
- Slingluff CL, Stidham KR, Ricci WM, Stanley WE, Seigler HF. (1994) Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg. 1994;219(2):120–130. https://doi.org/10.1097/00000658-199402000-00003. PMID:8129482
- Mansfield P, Lee J, Balch C. Cutaneous melanoma: current practice and surgical controversies. Curr Probl Surg. 1994;31(4):253–374. https://doi.org/10.1016/0011-3840(94)90025-6. PMID:8143489
- Stadelmann W, Rapaport D, Soong S. Prognostic clinical and pathologic features In: Balch C, Houghton A, Sober A, Soong S, eds. Cutaneous Melanoma. St Louis, Mo: Quality Medical Publishing Inc; 1998:11–35.
- Reintgen D, Rapaport D, Tanabe K. Lymphatic mapping and sentinel lymphadenectomy. In: Balch C, Houghton A, Sober A, Soong S-j, eds. Cutaneous Melanoma. St. Louis: Quality Medical Publishing; 1997:239.
- Kim SH, Garcia C, Rodriquez J, Coit DG. Prognosis of thick cutaneous melanoma. J Am Coll Surg. 1999;188:241–247. https://doi.org/10.1016/S1072-7515(98)00296-8 PMID:10065812
- Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥ 4 mm) primary melanoma. Ann Surg Oncol. 2000;7(2):160–165. https://doi.org/10.1007/s10434-000-0160-4 PMID:10761797
- Salti GI, Kansagra A, Warso MA, Ronan SG, Das Gupta TK. Clinical node-negative thick melanoma. Arch Surg. 2002;137:291–295. https://doi.org/10.1001/archsurg.137.3.291 PMID:11888451
- Perrott RE, Glass LF, Reintgen DS, Fenske NA. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol. 203;49(4):567–588. https://doi.org/10.1067/S0190-9622(03)02136-4
- Jacobs IA, Chang CK, Salti GI. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Am Surg. 2004;70(1):59–62. PMID:14964550
- Schneebaum S, Briele HA, Walker MJ, Greager J, Wood DK, Ronan SG. Cutaneous thick melanoma: prognosis and treatment. Arch Surg. 1987;122(6):707–711. https://doi.org/10.1001/archsurg.1987.01400180089017 PMID:3579586
- Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, Murad TM. A comparison of prognostic factors and surgical results in 1,786 patients with localized (Stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982;196(6):677–684. https://doi.org/10.1097/00000658-198212001-00011 PMID:7149819
- Crowley NJ, Seigler HF. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer. 1990;66:2522–2527. https://doi.org/10.1002/1097-0142(19901215)66:12%3c2522::AID-CNCR2820661213%3e3.0.CO;2-Z PMID:2249194
- Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997;225(1):1–14. https://doi.org/10.1097/00000658-199701000-00001 PMID:8998115
- Gutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is the most important prognostic factor for thick (≥ 4 mm) melanomas. JDDG. 2008;6(3):198–203. https://doi.org/10.1111/j.1610-0387.2007.06569.xPMID:18093216
- Balch CM, Soong S-J, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224(3):255–263. https://doi.org/10.1097/00000658-199609000-00002 PMID:8813254
- Rondelli F, Vedovati MC, Becattini C, et al. Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta-analysis. J Eur Acad Dermatol Venereol. 2012;26(5):560–565. https://doi.org/10.1111/j.1468-3083.2011.04109.x PMID:21561487
- Meguerditchian AN, Asubonteng K, Young C, Lema B, Wilding G, Kane JM 3rd. Thick primary melanoma has a heterogeneous tumour biology: an institutional series. Word J Surg Oncol. 2011;9:40–46. https://doi.org/10.1186/1477-7819-9-40
- Scoggins CR, Bowen AL, Martin RC 2nd, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg. 2010;145(7):622–627. https://doi.org/10.1001/archsurg.2010.115 PMID:20644123
- Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C. Sentinel lymph node mapping for thick (≥ 4 mm) melanoma: should we be doing it? Ann Surg Oncol. 2003;10(4):408–415. https://doi.org/10.1245/ASO.2003.03.055 PMID:12734090
- Van der Esch EP, Cascinelli N, Preda F, Morabito A, Bufalino R. Stage I melanoma of the skin: evaluation of prognosis accordino to histologic characteristics. Cancer. 1981;48(7):1668–1673. https://doi.org/10.1002/1097-0142(19811001)48:7%3c1668::AID-CNCR2820480732%3e3.0.CO;2-9 PMID:7284966
- Day CL Jr, Lew RA, Mihm MC Jr, et al. A multivariate analysis of prognostic factors for melanoma patients with lesions ≥ 3.65 mm in thickness. Ann Surg. 1982;195(1):44–49. https://doi.org/10.1097/00000658-198201001-00007%2010.1097/00000658-198201001-00005 PMID:7055383
- Balch CM, Soong S, Shaw HM. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM. Cutaneous Melanoma. Philadelphia, JB: Lippincott, 1992;165–191.
- Elias EG, Didolkar MS, Goel IP, et al. Deeply invasive cutaneous malignant melanoma. Surg Gynecol Obstet. 1981;153(1):67–70. PMID:7244978
- Kapelanski DP, Block GE, Kaufman M. Characteristics of the primary lesion of malignant melanoma as a guide to prognosis and therapy. Ann Surg. 1979;189(2):225–235. https://doi.org/10.1097/00000658-197902000-00015 PMID:426555
- Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188(6):732–742. https://doi.org/10.1097/00000658-197812000-00004 PMID:736651
- Bear HD, Neifeld JP, Kay S. Prognosis of level V malignant melanoma. Cancer. 1985;55(6):1167–1171. https://doi.org/10.1002/1097-0142(19850315)55:6%3c1167::AID-CNCR2820550604%3e3.0.CO;2-3 PMID:3971289
- Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg. 1990;125(3):322–326. https://doi.org/10.1001/archsurg.1990.01410150044009 PMID:2306180
- Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients; validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–3634. https://doi.org/10.1200/JCO.2001.19.16.3635%2010.1200/JCO.2001.19.16.3622 PMID:11504744
- Cecchi R, Buralli L, Innocenti S, Seghieri G, De Gaudio C. Sentinel lymph node biopsy in patients with thick (= 4 mm) melanoma: a single-centre experience. J Eur Acad Dermatol Venereol. 2007;21(6):758–761. https://doi.org/10.1111/j.1468-3083.2006.02072.x PMID:17567303
- Vermeeren L, van der Ent FWC, Sastrowijoto SH, Hulsewè KWE. Thick melanoma: prognostic value of positive sentinel nodes. World J Surg. 2009;33:2464–2468. https://doi.org/10.1007/s00268-009-0159-3 PMID:19649757
- Göppner D, Ulrich J, Pokrywka A, Peters B, Gollnick H, Leverkus M. Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high-risk tumors >4 mm. Dermatology. 2011;222(1):59–66. https://doi.org/10.1159/000322495 PMID:21196701
- Covarelli P, Vedovati MC, Becattini C, et al. The sentinel node biopsy in patients with thick melanoma: outcome analysis from a single-institution database. In vivo. 2011;25:439–444. PMID:21576420
- Hinz T, Ahmadzadehfar H, Wierzbicki A, et al. Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution. Eur J Nucl Med Mol Imaging. 2012;39(8):1316–1325. https://doi.org/10.1007/s00259-012-2139-3 PMID:22618833
- Rughani MG, Swan MC, Adams TS, et al. Sentinel node status predicts survival in thick melanomas: The Oxford perspective. Eur J Surg Oncol. 2012;38(10):936–942. https://doi.org/10.1016/j.ejso.2012.04.011 PMID:22617251
- Kelly J, Redmond HP. The role of sentinel lymph node biopsy in patients with thick melanoma. A single centre experience. Surgeon. 2012;10(2):65–70. https://doi.org/10.1016/j.surge.2011.01.012 PMID:22385526
- Mozzillo N, Pennacchioli E, Gandini S, et al. Sentinel node biopsy in thin and thick melanoma. Ann Surg Oncol. 2013;20(8):2780–2786. https://doi.org/10.1245/s10434-012-2826-0 PMID:23720068
- White I, Fortino J, Curti B, Vetto J. Clinical impact of sentinel lymph node biopsy in patients with thick (>4 mm) melanomas. Am J Surg. 2014;207(5):702–707. https://doi.org/10.1016/j.amjsurg.2013.12.022 PMID:24791630
- Kachare SD, Singla P, Vohra NA, Zervos EE, Wong JH, Fitzgerald TL. Sentinel lymph node biopsy is prognostic but not therapeutic for thick melanoma. Surgery. 2015;158(3):662–668. https://doi.org/10.1016/j.surg.2015.05.012 PMID:26096561
- Yamamoto M, Fisher KJ, Wong JY, et al. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer. 2015;121(10):1628–1636. https://doi.org/10.1002/cncr.29239 PMID:25677366
- Gyorki DE, Sanelli A, Herschtal A, et al. Sentinel lymph node biopsy in T4 melanoma: an important risk-stratification tool. Ann Surg Oncol. 2016;23(2):579–584. https://doi.org/10.1245/s10434-015-4894-4 PMID:26471491
- Bello DM, Han G, Jackson L, et al. The prognostic significance of sentinel lymph node status for patients with thick melanoma. Ann Surg Oncol. 2016;23(Suppl):938–945. https://doi.org/10.1245/s10434-016-5502-y PMID:27527717
- Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9(7):637–645.https://doi.org/10.1007/BF02574479. PMID:12167577
- Borgognoni L, Urso C, Vaggelli L, Brandani P, Gerlini G, Reali UM. Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: technical advantages using computer-assisted gamma probe with adjustable collimation. Melanoma Res. 2004;14(4):311–319. https://doi.org/10.1097/01.cmr.0000133968.28172.6e PMID:15305163
- Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol. 2003;200(3):314–319. https://doi.org/10.1002/path.1365 PMID:12845627
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. https://doi.org/10.1080/01621459.1958.10501452
- Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187–202.
- Cherpelis BS, Haddad F, Messina J, et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol. 2001;44(5):762–766. https://doi.org/10.1067/mjd.2001.112346 PMID:11312421
- Fujisawa Y, Otsuka F. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicentre, retrospective study of 291 Japanese patients. Melanoma Res. 2012;22:362–367. https://doi.org/10.1097/CMR.0b013e328355e558PMID:22713797
- Pasquali S, Haydu LE, Scolyer RA, et al. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. Ann Surg. 2013;258(1):152–157. https://doi.org/10.1097/SLA.0b013e31828421e1 PMID:23426339
- Zippel DB, Shapira R, Kuchuk I, et al. Outcome of thick (>4 mm) node-negative melanomas. Isr Med Assoc J. 2009;11(11):669–672. PMID:20108553
- Sondak VK, Swetter SM, Berwick MA. Gender disparities in patients with melanoma: breaking the glass ceiling. J Clin Oncol. 2012;30(18):2177–2178. https://doi.org/10.1200/JCO.2011.41.3849 PMID:22547593
- Dixon A, Steinman H, Anderson S, et al. Routine usage of sentinel node biopsy in melanoma management must cease. Br J Dermatol. 2016;175(6):1340–1341. https://doi.org/10.1111/bjd.14769 PMID:27996136
- Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–767. https://doi.org/10.1016/S1470-2045(16)00141-8 PMID:27161539
- Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2222. https://doi.org/10.1056/NEJMoa1613210 PMID:28591523
- Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72:780–785. https://doi.org/10.1016/j.jaad.2015.01.009 PMID: 25748297